SEC Filing Analysis: Spyre Therapeutics, Inc. (SYRE)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The CEO of Spyre Therapeutics, Cameron Turtle, executed a planned sale of common stock valued at approximately $1.05 million under a Rule 10b5-1 trading plan.
• Market Impact: The transaction is considered routine and is unlikely to have a material impact on the stock, given its small size relative to the company's market capitalization and the pre-arranged nature of the sale.

Company Information

Field	Value
Company	Spyre Therapeutics, Inc.
Ticker Symbol	SYRE
CIK	0001636282
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Turtle Cameron
CIK	0001758363
Title/Position	Chief Executive Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-03
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	45,000
Price Per Share	$23.33 (Weighted Average)
Total Value	$1,049,800
Shares Owned After	701,907
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,049,800
% of Market Cap	0.057%
Shares Transacted	45,000
% of Shares Outstanding	0.075%
Post-Transaction Ownership	701,907 shares (1.16% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $1.05 million sale is minor against Spyre Therapeutics' $1.84 billion market capitalization.
• Ownership Concentration: The sale reduced the CEO's holdings by approximately 6%, from 746,907 to 701,907 shares. His post-transaction ownership remains significant at 1.16% of all outstanding shares.
• Transaction Significance: Both the value as a percentage of market cap (0.057%) and shares as a percentage of outstanding (0.075%) are well below the thresholds for moderate or high significance. This points to a routine portfolio management action rather than a change in the insider's outlook on the company.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Sales conducted under a pre-disclosed Rule 10b5-1 plan are generally not considered indicative of an insider's current sentiment, as the decision to sell was made at an earlier date. The small size of the transaction further supports a neutral impact.

Volume & Sentiment

• Expected Volume Impact: Minimal. The transaction size is unlikely to cause a noticeable deviation from average trading volume.
• Sentiment Indicator: Neutral. The market typically discounts pre-planned sales by insiders.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly states the sale was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. This provides a structured, pre-planned method for insiders to sell shares without being accused of trading on non-public information.